{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:33:27Z","timestamp":1774488807034,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s12519-019-00303-w","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T07:03:18Z","timestamp":1567666998000},"page":"595-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China"],"prefix":"10.1007","volume":"15","author":[{"given":"Yao","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Zi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Jing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1342-5537","authenticated-orcid":false,"given":"Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"303_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212\u20139.","journal-title":"Vaccine"},{"key":"303_CR2","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095\u2013128.","journal-title":"Lancet"},{"key":"303_CR3","first-page":"570","volume":"33","author":"GQ Wang","year":"2015","unstructured":"Wang GQ, Wang FS, Cheng J, Ren H, Zhuang H, Sun J, et al. Guidelines for treatment of chronic hepatitis B (2015). Chin J of Exp Clinic Infect Dis (Electron Ed). 2015;33:570\u201389.","journal-title":"Chin J of Exp Clinic Infect Dis (Electron Ed)"},{"key":"303_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261\u201383.","journal-title":"Hepatology"},{"key":"303_CR5","first-page":"370","volume":"2017","author":"EASL","year":"2017","unstructured":"EASL. EASL Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017:370\u201398.","journal-title":"J Hepatol"},{"key":"303_CR6","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1002\/hep.23934","volume":"52","author":"MM Jonas","year":"2010","unstructured":"Jonas MM, Block JM, Haber BA, Karpen SJ, London WT, Murray KF, et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology. 2010;52:2192\u2013205.","journal-title":"Hepatology"},{"key":"303_CR7","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jhep.2013.05.016","volume":"59","author":"EM Sokal","year":"2013","unstructured":"Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European society of pediatric gastroenterology Hepatology and Nutrition. J Hepatol. 2013;59:814\u201329.","journal-title":"J Hepatol"},{"key":"303_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/MPG.0b013e318197196e","volume":"48","author":"U Shah","year":"2009","unstructured":"Shah U, Kelly D, Chang M, Fujisawa T, Heller S, Gonzalez-Peralta RP, et al. Management of chronic hepatitis B in children. J Pediatr Gastroenter and Nutr. 2009;48:399\u2013404.","journal-title":"J Pediatr Gastroenter and Nutr"},{"key":"303_CR9","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jhep.2012.03.036","volume":"57","author":"M Paganelli","year":"2012","unstructured":"Paganelli M, Stephenne X, Sokal EM. Chronic hepatitis B in children and adolescents. J Hepatol. 2012;57:885\u201396.","journal-title":"J Hepatol"},{"key":"303_CR10","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok AS, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"key":"303_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"EASL","year":"2012","unstructured":"EASL. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167\u201385.","journal-title":"J Hepatol"},{"key":"303_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1\u201398.","journal-title":"Hepatol Int"},{"key":"303_CR13","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0016-5085(98)70318-X","volume":"114","author":"EM Sokal","year":"1998","unstructured":"Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology. 1998;114:988\u201395.","journal-title":"Gastroenterology"},{"key":"303_CR14","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/hep.30050","volume":"68","author":"S Wirth","year":"2018","unstructured":"Wirth S, Zhang H, Hardikar W, Schwarz KB, Sokal E, Yang W, et al. Efficacy and safety of peginterferon Alfa-2a (40KD) in children with chronic hepatitis B: the PEG-B-ACTIVE study. Hepatology. 2018;68:1681\u201394.","journal-title":"Hepatology"},{"key":"303_CR15","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.dld.2014.08.032","volume":"46","author":"SA El","year":"2014","unstructured":"El SA, Omar A. Treatment of children with HBeAg-positive chronic hepatitis B: a systematic review and meta-analysis. Dig Liver Dis. 2014;46:1103\u201310.","journal-title":"Dig Liver Dis"},{"key":"303_CR16","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/hep.24555","volume":"54","author":"YF Liaw","year":"2011","unstructured":"Liaw YF, Jia JD, Chan HLY, Han KH, Tanwandee T, Chuang WL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011;54:1591\u20139.","journal-title":"Hepatology"},{"key":"303_CR17","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"352","author":"G Lau","year":"2005","unstructured":"Lau G, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. New Engl J Med. 2005;352:2682\u201395.","journal-title":"New Engl J Med"},{"key":"303_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","volume":"48","author":"G Fattovich","year":"2008","unstructured":"Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335\u201352.","journal-title":"J Hepatol"},{"key":"303_CR19","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1086\/521864","volume":"45","author":"R Iorio","year":"2007","unstructured":"Iorio R, Giannattasio A, Cirillo F, Alessandro LD, Vegnente A. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis. 2007;45:943\u20139.","journal-title":"Clin Infect Dis"},{"key":"303_CR20","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.amjmed.2005.02.033","volume":"119","author":"Y Arase","year":"2006","unstructured":"Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med. 2006;119:e9\u201316.","journal-title":"Am J Med"},{"key":"303_CR21","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/hep.23464","volume":"51","author":"J Simonetti","year":"2010","unstructured":"Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B Virus. Hepatology. 2010;51:1531\u20137.","journal-title":"Hepatology"},{"key":"303_CR22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1086\/341508","volume":"186","author":"G Marx","year":"2002","unstructured":"Marx G, Martin SR, Chicoine JF, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis. 2002;186:295\u2013301.","journal-title":"J Infect Dis"},{"key":"303_CR23","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/hep.21077","volume":"43","author":"F Bortolotti","year":"2006","unstructured":"Bortolotti F, Guido M, Bartolacci S, Cadrobbi P, Crivellaro C, Noventa F, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology. 2006;43:556\u201362.","journal-title":"Hepatology"},{"key":"303_CR24","first-page":"587","volume":"54","author":"SS Zhu","year":"2016","unstructured":"Zhu SS, Dong Y, Wang LS, Xu ZQ, Chen DW, Gan Y, et al. A retrospective study on the liver pathological characteristics and the effect of antiviral treatment for 1\u20137 years old children with heptitis B e antigen negative chronic hepatitis B. Chin J Pediatr. 2016;54:587\u201391.","journal-title":"Chin J Pediatr"},{"key":"303_CR25","first-page":"1","volume":"33","author":"H Zhuang","year":"2013","unstructured":"Zhuang H, Weng XH. Drug resistance and management of nucleoside and nucleotide drugs for chronic hepatitis B treatment. Chin Prev Med. 2013;33:1\u201311.","journal-title":"Chin Prev Med"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-019-00303-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12519-019-00303-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-019-00303-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T23:41:15Z","timestamp":1599176475000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12519-019-00303-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["303"],"URL":"https:\/\/doi.org\/10.1007\/s12519-019-00303-w","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"24 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.\u00a0Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}